{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670318971810176.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.510290321"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.510290321"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-199903000-00037"}},{"identifier":{"@type":"NAID","@value":"30015135361"}}],"dc:title":[{"@value":"Efficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Bb"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>This placebo controlled, double–blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)–negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n = 60) or placebo for 26 weeks (n = 65). Patients who were HBV DNA positive at week 24 were withdrawn at week 26. The primary efficacy endpoint was loss of serum HBV DNA plus normalization of alanine transaminase (ALT) at week 24. A significantly higher proportion of patients receiving lamivudine (63%) had a complete response at week 24 compared with patients receiving placebo (6%) (<jats:italic toggle=\"yes\">P</jats:italic> < .001). Secondary efficacy parameters included histological response from baseline to week 52 in the lamivudine–treated patients. At week 52, 60% of lamivudine–treated patients with liver biopsy specimens available showed histological improvement (≥2–point reduction in Knodell necro–inflammatory score), 29% showed no change, and 12% worsened. In a ranked assessment of pretreatment and post–treatment biopsy pairs 11% improved, 86% showed no change, and 2% worsened in fibrosis. At week 52, 27% of patients receiving lamivudine had YMDD (tyrosine–methionine–aspartate–aspartate amino acid motif of HBV polymerase) variant HBV. The incidence of adverse events and laboratory abnormalities was similar in both groups. In conclusion, lamivudine treatment results in a significant virological and biochemical improvement compared with placebo, induces an improvement or no change in histology in most patients, and is well tolerated. The response to lamivudine therapy in HBeAg–negative patients is similar to the response reported in previous studies of patients with HBeAg–positive chronic hepatitis B.</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670318971810050","@type":"Researcher","foaf:name":[{"@value":"Nicolaos C. Tassopoulos"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318971810049","@type":"Researcher","foaf:name":[{"@value":"Riccardo Volpes"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318971810181","@type":"Researcher","foaf:name":[{"@value":"Giuseppe Pastore"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318971810182","@type":"Researcher","foaf:name":[{"@value":"Jenny Heathcote"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318971810178","@type":"Researcher","foaf:name":[{"@value":"Maria Buti"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318971810176","@type":"Researcher","foaf:name":[{"@value":"Robert D. Goldin"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318971810180","@type":"Researcher","foaf:name":[{"@value":"Sasha Hawley"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318971810179","@type":"Researcher","foaf:name":[{"@value":"Judy Barber"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318971810177","@type":"Researcher","foaf:name":[{"@value":"Lynn Condreay"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302173273927296","@type":"Researcher","foaf:name":[{"@value":"Fraser D. Gray"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"1999-03","prism:volume":"29","prism:number":"3","prism:startingPage":"889","prism:endingPage":"896"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.510290321"},{"@id":"https://journals.lww.com/01515467-199903000-00037"}],"createdAt":"2004-07-28","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861707377081472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204241440384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lamivudine as an Alternative Therapy for Interferon-Resistant Chronic Hepatitis B and the Characteristics of Hepatitis B Virus: A Case Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204788892288","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Forefront of the viral chronic hepatitis treatment. Treatment of the case for which the treatment plans can not be decided. 2. Treatment of the case which is negative in HBe antigen and repeats liver function abnormality."},{"@value":"ウイルス性慢性肝炎治療の最先端―治療方針に迷う症例に対する治療―２．ＨＢｅ抗原陰性，肝機能異常を繰り返す症例に対する治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204791499136","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"急性Ｂ型肝炎重症例にラミブジン療法を試みた１症例"},{"@language":"en","@value":"A Case of Severe Acute Hepatitis B Treated by Lamivudine Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792470016","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"慢性肝炎治療の新たな展開　２　　Ｂ型肝炎　　ラミブジンの適応と治療成績"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792496896","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"慢性Ｂ型肝炎に対するラミブジン治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679247500800","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological and clinical profile of lamivudine(Zefix)."},{"@language":"ja","@value":"抗ＨＢＶ薬ラミブジン（ゼフィックス錠１００）の薬理作用と臨床効果"},{"@value":"新薬紹介総説 抗HBV薬ラミブジン(ゼフィックス錠100)の薬理作用と臨床効果"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ コウHBVヤク ラミブジン ゼフィックスジョウ 100 ノ ヤクリ サヨウ ト リンショウ コウカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679767662848","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of decompensated hepatitis B virus-related cirrhosis successfully treated with lamivudine and adefovir allowing repeated treatments for hepatocellular carcinomas"},{"@language":"ja","@value":"ＬａｍｉｖｕｄｉｎｅおよびＡｄｅｆｏｖｉｒ治療により肝細胞癌の治療反復が可能であったＢ型非代償性肝硬変の１例"},{"@value":"症例報告 LamivudineおよびAdefovir治療により肝細胞癌の治療反復が可能であったB型非代償性肝硬変の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク Lamivudine オヨビ Adefovir チリョウ ニ ヨリ カン サイボウガン ノ チリョウ ハンプク ガ カノウ デ アッタ Bガタ ヒダイショウセイ カンコウヘン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009749780572160","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750285604864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of research and management of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225164254208","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lamivudine treatment for acute exacerbation of hepatitis B in patients undergoing immunosuppressive therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225550106880","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225907607296","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261549594159616","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Much remains to be solved in lamivudine treatment for HBV-associated liver diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550386807424","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Improving outcomes for patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550748835968","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950399994458240","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lamivudine as an Alternative Therapy for Interferon-Resistant Chronic Hepatitis B and the Characteristics of Hepatitis B Virus : A Case Report"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.510290321"},{"@type":"CIA","@value":"30015135361"},{"@type":"CROSSREF","@value":"10.1620/tjem.191.247_references_DOI_ogl9ULBz78CaATr5d4Nw19R18O"},{"@type":"CROSSREF","@value":"10.1254/fpj.120.55_references_DOI_ogl9ULBz78CaATr5d4Nw19R18O"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_ogl9ULBz78CaATr5d4Nw19R18O"},{"@type":"CROSSREF","@value":"10.2957/kanzo.46.262_references_DOI_ogl9ULBz78CaATr5d4Nw19R18O"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_ogl9ULBz78CaATr5d4Nw19R18O"},{"@type":"CROSSREF","@value":"10.1111/hepr.13768_references_DOI_ogl9ULBz78CaATr5d4Nw19R18O"}]}